New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Key Highlights
- ➤Lenacapavir one-year persistence reached 85.6%, versus 46.3% for daily oral F/TDF
- ➤Zero HIV acquisitions occurred among lenacapavir recipients during the 52-week study
- ➤PURPOSE 5 persistence difference was 39.3 percentage points, statistically significant at p<0.0001
- ➤One HIV acquisition occurred in the F/TDF group, with drug levels indicating fewer than two weekly doses
- ➤Lenacapavir injection serious adverse events were 3.9%; no treatment-related serious events occurred
Expert Statements
Chloe Orkin, Clinical Professor of Infection and Inequities, Queen Mary University of London
“While starting on PrEP is important, persisting on PrEP is critical to preventing HIV acquisition”
Chloe Orkin, Clinical Professor of Infection and Inequities, Queen Mary University of London
“In PURPOSE 5, people in France and the United Kingdom receiving twice-yearly lenacapavir injections were much more likely to keep taking PrEP effectively compared with those receiving daily PrEP tablets.”
Chloe Orkin, Clinical Professor of Infection and Inequities, Queen Mary University of London
“These findings suggest long-acting injections for PrEP may help address a very important barrier to sustained HIV prevention for people who need it.”
Chloe Orkin, Clinical Professor of Infection and Inequities, Queen Mary University of London
“It is notable that the study was able to reach a high proportion of new PrEP users.”
Jared Baeten, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences
“This study was designed specifically to evaluate one of the most important challenges in HIV prevention today: helping people remain on PrEP for as long as they need protection”
Jared Baeten, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences
“These results demonstrate that twice-yearly lenacapavir has the potential to help close the gap between starting PrEP and staying on PrEP which can have an important impact on our efforts to end the HIV epidemic in Europe and around the world.”
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
– Zero HIV Acquisitions Occurred Among Participants Receiving Twice-Yearly Lenacapavir During the 52-Week Study Period –
Get started
Create a free account to read the full story.